Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Brain tumor Stories

2013-11-30 23:20:01

In response to an article published by Medical XPress, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, discusses a new pediatric pump that could drastically improve treatment for pediatric brain cancer. New York, NY (PRWEB) November 30, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by Medical XPress on November 25th that discusses how a new implantable pump...

2013-11-29 23:23:38

In response to an article published by U.S. News & World Report, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, discusses a new drug combination that could eradicate glioblastoma. Bohemia, NY (PRWEB) November 29, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by U.S. News & World Report on November 25, 2013 that discusses how a new drug cocktail may...

2013-11-27 23:04:25

Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating cancer with cell and gene therapies – has provided a $500,000 grant to combat glioblastoma, one of the most difficult types of brain cancer to treat. Visit http://www.ACGTFoundation.org. United States and Canada (PRWEB) November 27, 2013 Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating...

2013-11-26 16:24:43

HOUSTON, Nov. 26, 2013 /PRNewswire/ -- The Burzynski Clinic (BC) announced today the successful treatment of a child with recurrent diffuse intrinsic pontine gliosarcoma (DIPGGS) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco. Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The pontine location of this tumor is unusual, invariably fatal and successful treatment was not yet described in medical literature. The...

2013-11-26 16:24:41

HOUSTON, Nov. 26, 2013 /PRNewswire/ -- The Burzynski Clinic (BC) announced today that it has presented the results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in children with recurrent high-grade glioma at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco. There are no standard treatment recommendations for children with high-grade glioma after recurrence. New therapies are required for patients whose tumor recurs after...

2013-11-26 16:24:38

HOUSTON, Nov. 26, 2013 /PRNewswire/ -- The Burzynski Clinic (BC) announced today that it has presented the results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent glioblastoma multiforme (GBM) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco. GBM accounts for 60% of the primary brain tumors in adults and represents the most frequently occurring and the most malignant form of such tumors. Treatment...

2013-11-26 16:24:37

HOUSTON, Nov. 26, 2013 /PRNewswire/ -- The Burzynski Clinic (BC) announced today that it made a presentation of the results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in pediatric recurrent diffuse intrinsic pontine glioma (DIPG) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco. Brainstem gliomas are rare tumors in which DIPG comprises a distinct group. Numerous trials have been conducted in DIPG without proving...

2013-11-26 08:27:27

Additional Preclinical Studies Demonstrate Potential for Intravenous Administration of Toca 511 and Use in Combination with Temozolomide and Radiation SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Tocagen Inc. today announced that interim clinical data from two ongoing Phase I investigational studies presented at the Society for Neuro-Oncology (SNO) Annual Meeting in San Francisco showed that Toca 511 administration followed by courses of oral Toca FC was safe and well tolerated in 60...

2013-11-25 15:15:08

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal. A UZH research team has now achieved success with a novel form of treatment that involves encouraging the body’s own immune system to recognise and eliminate cancer cells in the brain. Animal experiments show that it is relatively easy to treat cancer in the early stages. However, it is far more difficult to successfully treat...

2013-11-25 09:55:06

With standard care, median length of survival is 15 months after diagnosis of glioblastoma multiforme -- and only 10 percent survive more than 5 years Eight of 16 patients participating in a study of an experimental immune system therapy directed against the most aggressive malignant brain tumors – glioblastoma multiforme – survived longer than five years after diagnosis, according to Cedars-Sinai researchers, who presented findings Nov. 23 at the Fourth Quadrennial Meeting of the...